Orchid Chemicals & Pharmaceuticals has agreed to sell its injectables business to the US-based Hospira for around $400 million (Rs 1,850 crore), a valuation that represents a 20% premium to the Chennai-based firm’s market value and greatly boosts its financial flexibility.

Cubist Pharmaceuticals, Inc a leading acute care therapeutics company, announced the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc, a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

With the Japanese government's move towards generics, Japanese pharmaceutical market seems to have become an attractive destination for India.

Another year of change and consolidation in the pharma industry began with the announcement of two mega-mergers and a long-expected takeover - and ends with the fallout of those mergers beginning to bite.